Dezandrodeg
| Clinical data | |
|---|---|
| Synonyms | AR-LDD; BMS-986365; BMS986365; CC-0094676; CC0094676; CC-94676; CC94676; CEL-007452; CEL007452 |
| Routes of administration | Oral[1] |
| Drug class | Antiandrogen; Androgen receptor antagonist; Androgen receptor degrader |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Chemical and physical data | |
| Formula | C41H45F3N8O5S |
| Molar mass | 818.92 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dezandrodeg (INN, USAN; developmental code names BMS-986365 and CC-94676) is an antiandrogen which is under development for the treatment of prostate cancer.[1][2][3][4] It is taken orally.[1] The drug acts as a dual androgen receptor antagonist and androgen receptor degrader.[1][2][3][4] It is under development by Celgene Corporation and Bristol-Myers Squibb.[1][2] As of June 2026, dezandrodeg is in phase 3 clinical trials for prostate cancer.[1][2] It was also under development for the treatment of solid tumors, but no recent development has been reported.[1]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Celgene Corporation". AdisInsight. 15 June 2026. Retrieved 28 July 2026.
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on Dezandrodeg with Synapse". Synapse. 3 July 2026. Retrieved 28 July 2026.
- ↑ 3.0 3.1 Nayak S, Norris JD, Ammirante M, Rychak E, Wardell SE, Liao D, Toyama B, Kandimalla R, Christoforou A, Tsuji T, Liu K, Tran M, Meiring J, Reiss S, Piccotti JR, Baughman JM, Fontanillo C, Khater M, Mortensen DS, Cathers B, Bence N, Pierce DW, Plantevin-Krenitsky V, Rathkopf D, Hansen JD, Hamann LG, Narla RK, Arora VK, McDonnell DP, Rolfe M, Xu S (January 2026). "Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer". Clinical Cancer Research. 32 (1): 224–241. doi:10.1158/1078-0432.CCR-25-0471. PMC 12770934 Check
|pmc=value (help). PMID 40788283 Check|pmid=value (help). - ↑ 4.0 4.1 Mortensen DS, Nayak S, Plantevin-Krenitsky V, Horn EJ, Meiring J, Reiss S, Peacock K, Zhao J, Ba X, Norris S, Alexander M, Correa M, Huang D, Brazeau JF, Sapienza J, Tehrani L, Nagy M, Whitefield B, Papa P, Harris R, Grant V, Norris JD, Ammirante M, Rychak E, Wardell SE, Tsuji T, Havens CG, Liu K, Piccotti JR, Dalvie D, Tang Y, Guerrero N, Sapinoso L, Baughman J, Cathers BE, Rolfe M, Hamann LG, McDonnell DP, Narla RK, Hansen JD, Xu S (July 2026). "Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365". Journal of Medicinal Chemistry. 69 (14): 16346–16362. doi:10.1021/acs.jmedchem.6c01590. PMID 42430428 Check
|pmid=value (help).
Template:Androgen receptor modulators
Template:Genito-urinary-drug-stub
This article "Dezandrodeg" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Dezandrodeg. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
